secwatch.observer — SEC 8-K summary
======================================

Issuer:     Benitec Biopharma Inc. (BNTC)
CIK:        0001808898
Form:       8-K
Filed at:   2024-03-08T23:59:59+00:00
Accession:  0001193125-24-063667
Event type: other_material
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Benitec Biopharma grants 666,558 stock options to CEO and executive director at $5.21
--------------------------------------------------------------------------------

- Compensation Committee approved nonqualified options for CEO Jerel Banks (466,554 shares) and Exec. Director Megan Boston (200,004 shares).
- Exercise price of $5.21 per share equals March 6, 2024 closing price.
- Options vest in three equal annual installments; full acceleration upon change in control.
- Grants made under the Company's 2020 Equity and Incentive Compensation Plan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1808898/000119312524063667/0001193125-24-063667-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1808898/000119312524063667/d782153d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-063667

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer